Adcytherix
French tech company | Builders Republic
About
Clinical-stage biopharma developing next-generation antibody-drug conjugates against hard-to-treat solid tumors — pairing targeting antibodies with novel cancer-killing payloads, with a lead candidate in early-stage human trials, built by the team that founded and sold Emergence Therapeutics to Eli Lilly.
Key facts
- Status
- Active
- Sectors
- Healthcare & Life Sciences
- Latest stage
- Series A
- Founded
- 2024
- City
- MARSEILLE
- Region
- Provence-Alpes-Côte d’Azur
- Tracked rounds
- 1
- Amount raised
- 105 M€ raised since 2020
Funding rounds
- Series A — 2025
Investors
- aMoon
- Andera Partners
- Angelini Ventures
- Bpifrance Large Venture
- Bpifrance Life Sciences Venture
- DawnBiopharma
- Kurma Partners
- Pontifax
- Pureos Bioventures
- RA Capital Management
- Surveyor Capital